Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2025HematologyOpen Access

Trends and disparities in immune thrombocytopenic purpura-related mortality in the United States: a retrospective study over 24 years

View Full Paper
Ask AI
Bookmark
Share

Authors

SAShahzaib AhmedHAHamza AshrafHAHaider Ashfaq

Discussion

Loading...

Member takes

Overview

Retrospective analysis identifies disparities in mortality trends related to immune thrombocytopenic purpura, suggesting gender and geographic influences.

Key Points

  • ITP-related mortality trends revealed significant disparities among gender and geographic locations, indicating underlying healthcare access issues.
  • From 1999 to 2022, there were 17,069 ITP-related deaths in the US, with males having a higher age-adjusted mortality rate at 0.22 compared to females' 0.17.
  • The analysis utilized age-adjusted mortality rates calculated through Joinpoint regression to assess trends and differences across various demographics.
  • Disparities, particularly among NH Whites and rural residents, highlight the effects of potential genetic predispositions and the need for targeted healthcare improvements.

Cite This Study

Ahmed et al. (2025) studied this question.

synapsesocial.com/papers/68d45e4431b076d99fa5e23dhttps://doi.org/10.1080/16078454.2025.2559334
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ethnic, racial, and geographic disparities in idiopathic thrombocytopenic purpura related mortality along the US-Mexico border from 1999 to 20202025
  2. 2Thrombotic thrombocytopenic purpura-related mortality trends among the United States population: A retrospective study using the CDC wonder database2025
  3. 3The unseen bleed- temporal and demographic patterns of thrombocytopenia mortality in the United States: A 25-year analysis of the CDC wonder database2025
  4. 4Rapid decrease in age-adjusted mortality rates associated with ITP following eltrombopag aand romiplostin approvals, but not in TMA following eculizumab approval, 1999-20232025
  5. 5A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA : A Multicenter Study of 390 Disease Episodes From 2017 to 20212025 · 3 citations